Theravance Biopharma Inc (TBPH) : Woodford Investment Management Llp scooped up 1,763,000 additional shares in Theravance Biopharma Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 15, 2016. The investment management firm now holds a total of 6,824,637 shares of Theravance Biopharma Inc which is valued at $153,144,854.Theravance Biopharma Inc makes up approximately 6.61% of Woodford Investment Management Llp’s portfolio.
Theravance Biopharma Inc opened for trading at $23.43 and hit $24.5699 on the upside on Wednesday, eventually ending the session at $24.08, with a gain of 2.99% or 0.7 points. The heightened volatility saw the trading volume jump to 1,79,899 shares. Company has a market cap of $925 M.
Other Hedge Funds, Including , Simplex Trading added TBPH to its portfolio by purchasing 3 company shares during the most recent quarter which is valued at $67.
Theravance Biopharma Inc. (Theravance Biopharma) is a biopharmaceutical company. The Company is engaged to create value from a diverse set of assets: an approved product; a development pipeline of mid- and late-stage assets and a productive research platform designed for long-term growth. VIBATIV (telavancin) its commercial product is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. TD-4208 is an investigational long-acting muscarinic antagonist (LAMA) being developed as a potential once-daily nebulized treatment for chronic obstructive pulmonary disease (COPD). Axelopran (TD-1211) is an investigational potential once-daily oral treatment for opioid-induced constipation (OIC). Its earlier-stage clinical assets represent approaches for potentially treating diseases of the lung and gastrointestinal tract and infectious disease.